Retrospective study to characterize patients with bullous pemphigoid presenting as eczema and prurigo diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036278

Enrollment

300

Registered

2025-07-03

Start date

2025-09-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L12.0 L20 L30.0 L30.8 L28.1 L28.2 L87.1 L12.8

Interventions

Group 1: patients with bullous pemphigoid: This retrospective study analyzes clinical, histological, immunological, and treatment-related data of patients with bullous pemphigoid and pruriginous derma

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: Initial diagnosis of one of the previously mentioned conditions within the data collection period.

Exclusion criteria

Exclusion criteria: Blister formation 2 months after the initial diagnosis.

Design outcomes

Primary

Measure	Time frame
Primary Endpoint: Comparison of demographic characteristics (e.g., age, sex), clinical presentation (e.g., skin manifestations, disease course), and diagnostic findings (e.g., histology, immunofluorescence, laboratory tests) between patients with non-bullous pemphigoid and those with pruriginous skin diseases (e.g., eczema, prurigo forms, reactive perforating dermatoses). Time of assessment: Data are collected retrospectively from electronic medical records at the time of initial diagnosis and follow-up visits documented between 2015 and 2021. Method: Analysis is based on standardized parameters recorded in clinical and diagnostic documentation. No questionnaires or additional measurements are used.	—

Measure

Time frame

Primary Endpoint: Comparison of demographic characteristics (e.g., age, sex), clinical presentation (e.g., skin manifestations, disease course), and diagnostic findings (e.g., histology, immunofluorescence, laboratory tests) between patients with non-bullous pemphigoid and those with pruriginous skin diseases (e.g., eczema, prurigo forms, reactive perforating dermatoses). Time of assessment: Data are collected retrospectively from electronic medical records at the time of initial diagnosis and follow-up visits documented between 2015 and 2021. Method: Analysis is based on standardized parameters recorded in clinical and diagnostic documentation. No questionnaires or additional measurements are used.

—

Secondary

Measure	Time frame
- Documentation and comparison of the frequency and severity of side effects, as well as remission data for different therapies of bullous pemphigoid. - retrospective assessment of the long-term course of bullous pemphigoid.	—

Countries

Germany

Contacts

Public ContactJasmin Marschner

Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie

jasmin.marschner@uniklinik-freiburg.de0761/27067020

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026